{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:55:40Z","timestamp":1787921740568,"version":"build-2784847793"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41375-023-02110-9","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T15:05:56Z","timestamp":1702998356000},"page":"502-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms"],"prefix":"10.1038","volume":"38","author":[{"given":"Tracy","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6151-3444","authenticated-orcid":false,"given":"Jacqueline M.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4598-9380","authenticated-orcid":false,"given":"Dawn","family":"Maze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-3899","authenticated-orcid":false,"given":"Aaron D.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Valiquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak W.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Minden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-9952","authenticated-orcid":false,"given":"Karen W. L.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"2110_CR1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386.","journal-title":"Lancet"},{"key":"2110_CR2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2110_CR3","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347\u201354.","journal-title":"Blood"},{"key":"2110_CR4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, et al. TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions. Cancer Discov. 2022;12:2516\u201329.","journal-title":"Cancer Discov"},{"key":"2110_CR5","doi-asserted-by":"crossref","unstructured":"Deeg HJ. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematology Am Soc Hematol Educ Program. (2005):167\u201373.","DOI":"10.1182\/asheducation-2005.1.167"},{"key":"2110_CR6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223\u201332.","journal-title":"Lancet Oncol"},{"key":"2110_CR7","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794\u2013803.","journal-title":"Cancer"},{"key":"2110_CR8","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429\u201340.","journal-title":"J Clin Oncol"},{"key":"2110_CR9","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","volume":"24","author":"LR Silverman","year":"2006","unstructured":"Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895\u2013903.","journal-title":"J Clin Oncol"},{"key":"2110_CR10","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","volume":"29","author":"T Prebet","year":"2011","unstructured":"Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322\u20137.","journal-title":"J Clin Oncol"},{"key":"2110_CR11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ccr.2014.05.006","volume":"26","author":"JM Mason","year":"2014","unstructured":"Mason JM, Lin DC, Wei X, Che Y, Yao Y, Kiarash R, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014;26:163\u201376.","journal-title":"Cancer Cell"},{"key":"2110_CR12","volume":"7","author":"Z Hu","year":"2006","unstructured":"Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.","journal-title":"BMC Genomics"},{"key":"2110_CR13","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ van de Vijver","year":"2002","unstructured":"van de Vijver MJ, He YD, van\u2019t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999\u20132009.","journal-title":"N Engl J Med"},{"key":"2110_CR14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10434-001-0729-6","volume":"8","author":"JC Macmillan","year":"2001","unstructured":"Macmillan JC, Hudson JW, Bull S, Dennis JW, Swallow CJ. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol. 2001;8:729\u201340.","journal-title":"Ann Surg Oncol"},{"key":"2110_CR15","first-page":"5327","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Wang H, Yan M, Yang X, Shen R, Ni X, et al. High LIN28A and PLK4 co\u2011expression is associated with poor prognosis in epithelial ovarian cancer. Mol Med Rep. 2018;18:5327\u201336.","journal-title":"Mol Med Rep"},{"key":"2110_CR16","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1158\/0008-5472.CAN-07-1887","volume":"67","author":"G Salvatore","year":"2007","unstructured":"Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007;67:10148\u201358.","journal-title":"Cancer Res"},{"key":"2110_CR17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood-2007-06-097774","volume":"111","author":"WJ Chng","year":"2008","unstructured":"Chng WJ, Braggio E, Mulligan G, Bryant B, Remstein E, Valdez R, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008;111:1603\u20139.","journal-title":"Blood"},{"key":"2110_CR18","doi-asserted-by":"crossref","first-page":"898474","DOI":"10.3389\/fgene.2022.898474","volume":"13","author":"XR Mu","year":"2022","unstructured":"Mu XR, Ma MM, Lu ZY, Liu J, Xue YT, Cao J, et al. Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines. Front Genet. 2022;13:898474.","journal-title":"Front Genet"},{"key":"2110_CR19","doi-asserted-by":"crossref","first-page":"e21476","DOI":"10.1096\/fj.202002454RR","volume":"35","author":"I Kolosenko","year":"2021","unstructured":"Kolosenko I, Goroshchuk O, Vidarsdottir L, Bjorklund AC, Dowdy SF, Palm-Apergi C. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. FASEB J. 2021;35:e21476.","journal-title":"FASEB J"},{"key":"2110_CR20","doi-asserted-by":"crossref","first-page":"154376","DOI":"10.1016\/j.prp.2023.154376","volume":"243","author":"S Chen","year":"2023","unstructured":"Chen S, Zhong L, Chu X, Wan P, Liu Z, Lu Y, et al. Downregulation of Polo-like kinase 4 induces cell apoptosis and G2\/M arrest in acute myeloid leukemia. Pathol Res Pract. 2023;243:154376.","journal-title":"Pathol Res Pract"},{"key":"2110_CR21","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1182\/blood-2022-170152","volume":"140","author":"E Ayoub","year":"2022","unstructured":"Ayoub E, Marupudi A, Nishida Y, Montoya RH, Mohanty V, Walter W, et al. Polyploidy Is necessary for apoptotic cell death in TP53-mut AML in response to polo-like-kinase 4 (PLK4) inhibition and results in caspase 3 cleavage. Blood. 2022;140:5941\u20133.","journal-title":"Blood"},{"key":"2110_CR22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37216-2","volume":"14","author":"A Portelinha","year":"2023","unstructured":"Portelinha A, da Silva Ferreira M, Erazo T, Jiang M, Asgari Z, de Stanchina E, et al. Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma. Nat Commun. 2023;14:1522.","journal-title":"Nat Commun"},{"key":"2110_CR23","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.18632\/oncotarget.13619","volume":"8","author":"I Lohse","year":"2017","unstructured":"Lohse I, Mason J, Cao PM, Pintilie M, Bray M, Hedley DW. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget. 2017;8:3064\u201371.","journal-title":"Oncotarget"},{"key":"2110_CR24","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.1719760115","volume":"115","author":"M Kawakami","year":"2018","unstructured":"Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, et al. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci USA. 2018;115:1913\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2110_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/jm5005336","volume":"58","author":"PB Sampson","year":"2015","unstructured":"Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK. et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5\u2022\u2019-methoxyspiro[cyclopropane-1,3\u2022\u2019-indolin]-2\u2022\u2019-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015;58:147\u201369.","journal-title":"J Med Chem"},{"key":"2110_CR26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41416-019-0517-3","volume":"121","author":"ZW Veitch","year":"2019","unstructured":"Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, et al. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. Br J Cancer. 2019;121:318\u201324.","journal-title":"Br J Cancer"},{"key":"2110_CR27","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"2110_CR28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419\u201325.","journal-title":"Blood"},{"key":"2110_CR29","doi-asserted-by":"crossref","first-page":"E10810","DOI":"10.1073\/pnas.1807871115","volume":"115","author":"M Kawakami","year":"2018","unstructured":"Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, et al. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci USA. 2018;115:E10810\u2013E1.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2110_CR30","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.32461","volume":"77","author":"CY Chan","year":"2023","unstructured":"Chan CY, Yuen VW, Chiu DK, Goh CC, Thu KL, Cescon DW, et al. Polo-like kinase 4 inhibitor CFI-400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. Hepatology. 2023;77:729\u201344.","journal-title":"Hepatology"},{"key":"2110_CR31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2110_CR32","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41375-020-0710-7","volume":"34","author":"B Yan","year":"2020","unstructured":"Yan B, Chen Q, Xu J, Li W, Xu B, Qiu Y. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Leukemia. 2020;34:1816\u201327.","journal-title":"Leukemia"},{"key":"2110_CR33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1593\/neo.04325","volume":"7","author":"J Li","year":"2005","unstructured":"Li J, Tan M, Li L, Pamarthy D, Lawrence TS, Sun Y. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia. 2005;7:312\u201323.","journal-title":"Neoplasia"},{"key":"2110_CR34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/nar\/gkt849","volume":"42","author":"M Fischer","year":"2014","unstructured":"Fischer M, Quaas M, Wintsche A, Muller GA, Engeland K. Polo-like kinase 4 transcription is activated via CRE and NRF1 elements, repressed by DREAM through CDE\/CHR sites and deregulated by HPV E7 protein. Nucleic Acids Res. 2014;42:163\u201380.","journal-title":"Nucleic Acids Res"},{"key":"2110_CR35","doi-asserted-by":"crossref","first-page":"e87918","DOI":"10.1371\/journal.pone.0087918","volume":"9","author":"A Ward","year":"2014","unstructured":"Ward A, Hudson JW. p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress. PLoS One. 2014;9:e87918.","journal-title":"PLoS One"},{"key":"2110_CR36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30\u20139.","journal-title":"J Clin Invest"},{"key":"2110_CR37","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood-2021-153436","volume":"138","author":"E Ayoub","year":"2021","unstructured":"Ayoub E, Montoya RH, Mohanty V, Walter W, Patsilevas T, Issa GC, et al. Targeting polo-like kinase 4 triggers polyploidy and apoptotic cell death in TP53-mutant acute myeloid leukemia. Blood. 2021;138:1167.","journal-title":"Blood"},{"key":"2110_CR38","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2022-165205","volume":"140","author":"CC Dang","year":"2022","unstructured":"Dang CC, Ng KLN, Lam W, Zeng XY, Zheng LC, Chan KC, et al. Inhibition of Polo-like kinase 4 induced both cell intrinsic and non-cell intrinsic anti-leukemia effects on TP53 -mutated acute myeloid leukemia. Blood. 2022;140:3099.","journal-title":"Blood"},{"key":"2110_CR39","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1101\/gad.207027.112","volume":"26","author":"AJ Holland","year":"2012","unstructured":"Holland AJ, Fachinetti D, Zhu Q, Bauer M, Verma IM, Nigg EA, et al. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle. Genes Dev. 2012;26:2684\u20139.","journal-title":"Genes Dev"},{"key":"2110_CR40","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1091\/mbc.e11-12-1043","volume":"23","author":"AJ Holland","year":"2012","unstructured":"Holland AJ, Fachinetti D, Da Cruz S, Zhu Q, Vitre B, Lince-Faria M, et al. Polo-like kinase 4 controls centriole duplication but does not directly regulate cytokinesis. Mol Biol Cell. 2012;23:1838\u201345.","journal-title":"Mol Biol Cell"},{"key":"2110_CR41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncb3270","volume":"18","author":"O Sercin","year":"2016","unstructured":"Sercin O, Larsimont JC, Karambelas AE, Marthiens V, Moers V, Boeckx B, et al. Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. Nat Cell Biol. 2016;18:100\u201310.","journal-title":"Nat Cell Biol"},{"key":"2110_CR42","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"2110_CR43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"2110_CR44","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, et al. Impact of Venetoclax and Azacitidine in treatment-naive patients with acute myeloid Leukemia and IDH1\/2 mutations. Clin Cancer Res. 2022;28:2753\u201361.","journal-title":"Clin Cancer Res"},{"key":"2110_CR45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"2110_CR46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/hematology.2022000354","volume":"2022","author":"J Versluis","year":"2022","unstructured":"Versluis J, Lindsley RC. Transplant for TP53-mutated MDS and AML: because we can or because we should? Hematology Am Soc Hematol Educ Program. 2022;2022:522\u20137.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2110_CR47","first-page":"293","volume":"2","author":"NO Machado","year":"2010","unstructured":"Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010;2:293\u2013300.","journal-title":"N Am J Med Sci"},{"key":"2110_CR48","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s10620-019-05778-1","volume":"64","author":"JD Kaunitz","year":"2019","unstructured":"Kaunitz JD, Akiba Y. Control of intestinal epithelial proliferation and differentiation: the microbiome, enteroendocrine l cells, telocytes, enteric nerves, and GLP, Too. Dig Dis Sci. 2019;64:2709\u201316.","journal-title":"Dig Dis Sci"},{"key":"2110_CR49","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette A, Chen J. SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39:173\u201384.","journal-title":"Trends Immunol"},{"key":"2110_CR50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The Cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"2110_CR51","doi-asserted-by":"crossref","unstructured":"Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan NN, et al. Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML. Blood. (2023).","DOI":"10.1182\/blood.2023019782"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02110-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T14:06:08Z","timestamp":1709561168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02110-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02110-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential conflicts of interest: JMM is an employee of Treadwell Therapeutics. BL was a consultant for AbbVie, Novartis, and Pfizer; and has received speakers\u2019 fees or honoraria from AbbVie, Alexion, Amgen, Astellas, Astex, Bristol Myers Squibb\/Celgene, Gilead\/KITE, Jazz Pharmaceuticals, Janssen, Novartis, Otsuka, Paladin, Pfizer, Roche, and Treadwell Therapeutics. MRB is a co-founder and an employee of Treadwell Therapeutics. SMC has received research funding from AbbVie, Agios, Bristol Myers Squibb\/Celgene, and Servier. VG has received research funding through his institution and honoraria from Novartis; and has served on the advisory board of AbbVie, Bristol Myers Squibb\/Celgene, GSK, Incyte, Morphosys, Novartis, and Pfizer. DM has received research support from Bristol Myers Squibb\/Celgene, Novartis, PharmaEsentia, and Takeda; has participated in advisory boards and received honoraria from Bristol Myers Squibb\/Celgene, Jazz, and Novartis; and has participated in consultancy for Pfizer. ADS has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees\/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals; is named on a patent application for the use of DNT cells to treat AML; and is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. ACS has consulted for and\/or received honoraria from and\/or received research support from AbbVie, Agios, Amgen, Astellas, Celgene\/BMS, GlycoMimetics, Jazz, Novartis, Paladin, Phebra, Pfizer, Servier, and Teva. MT has received research funding from Jazz. LN is an employee of Treadwell Therapeutics. TWM is a co-founder of Treadwell Therapeutics. KWLY was a consultant for Bristol Myers Squibb\/Celgene, F. Hoffmann-La Roche, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Shattuck Labs, Taiho Oncology, and Takeda; received research funding from Astex Pharmaceuticals, Forma Therapeutics, F. Hoffmann-La Roche, Forma Therapeutics, Genentech, Geron Corporation, Gilead Sciences, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Shattuck Labs, and Treadwell Therapeutics; and received honoraria from AbbVie, TaiHo, and Novartis. TM, DK, CJM, HS, DV, KM, XL, and MDM declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}